Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in Chronic Myelomonocytic Leukemia (CMML)
NCT03722407Phase 2Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Aug 2019
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in chronic myelomonocytic leukemia (CMML), sponsored by Moffitt Cancer Center. Started Aug 2019; status: active, not recruiting.
02
Drugs
03
Conditions
chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT03722407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03722407.